AOD9604 Obesity Drug
"Preparations are on track for commencement of the Company’s 300 patient Phase 2b human clinical trial of AOD9604 obesity drug, with the first patients expected to commence treatment in late-October.
The double-blind placebo-controlled trial involves the participation of five leading Australian hospitals. The primary aim of the study is to assess weight loss after three months daily dosing in male and female obese subjects".
Diet pills and A CURRENT AFFAIR. Warney has had banned substances before and current affairs. After watching A CURRENT AFFAIR tonight he may want to participate in a legal trial. Watch and see, share price up through $1.30 tomorrow.
Add to My Watchlist
What is My Watchlist?